NCT07209215 - ctDNA-Informed Management of Early-Stage Rectal Cancer | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

May 31, 2028

Conditions

Rectal AdenocarcinomaRectal CancerEarly-stage Rectal CancerLocally Advanced Rectal Adenocarcinoma

Interventions

DRUG

Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT)

Use of Signatera Genome ultra-sensitive ctDNA blood test post-total neoadjuvant therapy (TNT) for ctDNA-informed treatment management of early-stage rectal cancer.

Trial Locations (1)

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of California, Davis

OTHER